Fine‐tuning vascular fate during endothelial–mesenchymal transition
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
In the heart and other organs, endothelial–mesenchymal transition (EndMT) has emerged as an important developmental process that involves coordinated migration, differentiation, and proliferation of the endothelium. In multiple disease states including cancer angiogenesis and cardiovascular disease, the processes that regulate EndMT are recapitulated, albeit in an uncoordinated and dysregulated manner. Members of the transforming growth factor beta (TGFβ) superfamily are well known to impart cellular plasticity during EndMT by the timely activation (or repression) of transcription factors and miRNAs in addition to epigenetic regulation of gene expression. On the other hand, fibroblast growth factors (FGFs) are reported to augment or oppose TGFβ‐driven EndMT in specific contexts. Here, we have synthesized the currently understood roles of TGFβ and FGF signalling during EndMT and have provided a new, comprehensive paradigm that delineates how an autocrine and paracrine TGFβ/FGF axis coordinates endothelial cell specification and plasticity. We also provide new guidelines and nomenclature that considers factors such as endothelial cell heterogeneity to better define EndMT across different vascular beds. This perspective should therefore help to clarify why TGFβ and FGF can both cooperate with or oppose one another during the complex process of EndMT in both health and disease. Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689
Hinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M.-L., & Gabbiani, G. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070112 · Cited by 2,068
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466 · cited 1×
“TGF β signalling is strongly context-and cell type-dependent and is influenced by the microenvironment, interactions with auxiliary signalling pathways and transcription factors, and the epigenetic landscape [31,32].”
BackgroundFibroblast growth factors, their receptors and signaling
Powers, C. J., McLeskey, S. W., & Wellstein, A. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070165 · Cited by 1,332
Discovery of Endothelial to Mesenchymal Transition as a Source for Carcinoma-Associated Fibroblasts
Zeisberg, E. M., Potenta, S., Xie, L., Zeisberg, M., & Kalluri, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-3127 · Cited by 1,011
EndMT contributes to the onset and progression of cerebral cavernous malformations
Maddaluno, L., Rudini, N., Cuttano, R., Bravi, L., Giampietro, C., Corada, M., Ferrarini, L., Orsenigo, F., Papa, E., Boulday, G., et al. (2013) · Nature · doi:10.1038/nature12207 · Cited by 486
Chen, P.-Y., Qin, L., Barnes, C., Charisse, K., Yi, T., Zhang, X., Ali, R., Medina, P. P., Yu, J., Slack, F. J., et al. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.10.021 · Cited by 304 · cited 4×
“This antagonistic effect of bFGF is achieved by disabling multiple “nodes” in the TGF β signalling pathway [36–38].”
BackgroundMethodInfluentialGeneration of the epicardial lineage from human pluripotent stem cells
Witty, A. D., Mihic, A., Tam, R. Y., Fisher, S. A., Mikryukov, A., Shoichet, M. S., Li, R.-K., Kattman, S. J., & Keller, G. (2014) · Nature Biotechnology · doi:10.1038/nbt.3002 · Cited by 180 · cited 1×
“In a different study where epicardial-lineage cells were generated from human pluripotent stem cells, addition of bFGF enhanced TGFβ-stimulated expression of mesenchymal markers including SMA and vimentin, although bFGF-induced proliferation and expression of the EMT transcription factor SNAI1 was counteracted by TGFβ…”
BackgroundCo-ordinating Notch, BMP, and TGF-β signaling during heart valve development
Garside, V. C., Chang, A. C., Karsan, A., & Hoodless, P. A. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1197-9 · Cited by 160
Huang, M., Liu, T., Ma, P., Mitteer, R. A., Zhang, Z., Kim, H. J., Yeo, E., Zhang, D., Cai, P., Li, C., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84876 · Cited by 128 · cited 1×
“The loss of VEGFR2 may offer a mechanism for the ineffectiveness of anti-VEGF therapies in glioblastoma multiforme (GBM) [25].”
Background
Cited by
Endothelial to Mesenchymal Transition: Role in Physiology and in the Pathogenesis of Human Diseases
Piera-Velazquez, S., & Jimenez, S. A. (2019) · Physiological Reviews · doi:10.1152/physrev.00021.2018 · Cited by 662
Cell Type-Specific Roles of NF-κB Linking Inflammation and Thrombosis
Mussbacher, M., Salzmann, M., Brostjan, C., Hoesel, B., Schoergenhofer, C., Datler, H., Hohensinner, P., Basílio, J., Petzelbauer, P., Assinger, A., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00085 · Cited by 596
Pathological angiogenesis: mechanisms and therapeutic strategies
Dudley, A. C., & Griffioen, A. W. (2023) · Angiogenesis · doi:10.1007/s10456-023-09876-7 · Cited by 495
Self-citationTGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases
Pardali, E., Sanchez-Duffhues, G., Gomez-Puerto, M., & Ten Dijke, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102157 · Cited by 360
Reassessing endothelial-to-mesenchymal transition in cardiovascular diseases
Li, Y., Lui, K. O., & Zhou, B. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0023-y · Cited by 289
Endothelial-Mesenchymal Transition in Cardiovascular Disease
Alvandi, Z., & Bischoff, J. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.121.313788 · Cited by 218
Endothelial-to-Mesenchymal Transition in Cancer
Clere, N., Renault, S., & Corre, I. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00747 · Cited by 199
“…in tumors (Maishi et al., 2019; Goveia et al., 2020), combined with the diversity of signals emanating from TME, as fine tuning of EndMT appears to be under the control of several factors such as transforming growth factor-β (TGF-β) and basic fibroblast growth factor (bFGF) (Xiao and Dudley, 2017).”
BackgroundMicroRNA profiling reveals distinct profiles for tissue-derived and cultured endothelial cells
Kuosmanen, S. M., Kansanen, E., Sihvola, V., & Levonen, A.-L. (2017) · Scientific Reports · doi:10.1038/s41598-017-11487-4 · Cited by 48
Metadata
- Authors
- Xiao, L., & Dudley, A. C.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2016-11-10
- Volume
- 241
- Issue
- 1
- Pages
- 25-35
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2528651262
- Cited by
- 89
- References
- 12
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.